よむ、つかう、まなぶ。
資料4-2 レベチラセタム (17 ページ)
出典
| 公開元URL | https://www.mhlw.go.jp/stf/shingi2/0000198856_00023.html |
| 出典情報 | 医療上の必要性の高い未承認薬・適応外薬検討会議（第51回 6／8）《厚生労働省》 |
ページ画像
ダウンロードした画像を利用する際は「出典情報」を明記してください。
低解像度画像をダウンロード
プレーンテキスト
資料テキストはコンピュータによる自動処理で生成されており、完全に資料と一致しない場合があります。
テキストをコピーしてご利用いただく際は資料と付け合わせてご確認ください。
developing country. Seizure 2010; 19: 109-11.
15) Glauser T, et al. Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in
Children and Adults: Report of the Guideline Committee of the American Epilepsy Society.
Epilepsy Currents 2016; 16: 48-61.
16) Knake S, et al. Intravenous levetiracetam in the treatment of benzodiazepine refractory status
epilepticus. J Neurol Neurosurg Psychiatry 2008; 79: 588-9.
17) Uges JW, et al. Safety and pharmacokinetics of intravenous levetiracetam infusion as add-on in
status epilepticus. Epilepsia 2009; 50: 415-21.
18) Prasad M, et al. Anticonvulsant therapy for status epilepticus. Cochrane Database Syst Rev 2014;
CD003723.
19) Atmaca MM, et al. Intravenous levetiracetam treatment in status epilepticus: a prospective study.
Epilepsy Res 2015; 114: 13-22.
20) Mundlamuri RC, et al. Management of generalised convulsive status epilepticus (SE): A
prospective randomised controlled study of combined treatment with intravenous lorazepam
with either phenytoin, sodium valproate or levetiracetam – Pilot study. Epilepsy Research 2015;
114: 52-8.
21) Gujjar AR, et al. Intravenous levetiracetam vs phenytoin for status epilepticus and cluster
seizures: A prospective, randomized study. Seizure 2017; 49: 8-12.
22) Chakravarthi S, et al. Levetiracetam versus phenytoin in management of status epilepticus. J Clin
Neurosci 2015; 22: 959-63.
23) Lyttle MD, et al. Levetiracetam versus phenytoin for second-line treatment of paediatric
convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial. Lancet
2019; 393: 2125-34.
24) Nalisetty S, et al. Clinical Effectiveness of Levetiracetam Compared to Fosphenytoin in the
Treatment of Benzodiazepine Refractory Convulsive Status Epilepticus. Indian J Pediatr 2020;
87: 512-9.
25) Cock HR. Established Status Epilepticus Treatment Trial (ESETT). Epilepsia 2011; 52: 50-2.
26) Shih JJ, et al. Epilepsy treatment in adults and adolescents: Expert opinion, 2016. Epilepsy Behav
2017; 69: 186-222.
27) 久保田有一 他.【てんかん診療-すべての医師のための診断・治療のコツ-】てんかんの
最新治療 レベチラセタム（解説/特集）. 日本臨床 2018; 76: 952-8.
28) UPTODATE (This topic last updated: Jan 10, 2022)
29) Nakamura K, et al. Efficacy of levetiracetam versus fosphenytoin for the recurrence of seizures
after status epilepticus. Medicine 2017; 96: 25(e7206).
30) Nakamura K, et al. Changes in Real-world Practice Patterns of Antiepileptic Drugs for Status
Epilepticus: A Nationwide Observational Study in Japan. Neurol Med Chir 2020; 60: 156-63.
31) Nakamura K, et al. Levetiracetam vs. Fosphenytoin for Second-Line Treatment of Status
17
15) Glauser T, et al. Evidence-Based Guideline: Treatment of Convulsive Status Epilepticus in
Children and Adults: Report of the Guideline Committee of the American Epilepsy Society.
Epilepsy Currents 2016; 16: 48-61.
16) Knake S, et al. Intravenous levetiracetam in the treatment of benzodiazepine refractory status
epilepticus. J Neurol Neurosurg Psychiatry 2008; 79: 588-9.
17) Uges JW, et al. Safety and pharmacokinetics of intravenous levetiracetam infusion as add-on in
status epilepticus. Epilepsia 2009; 50: 415-21.
18) Prasad M, et al. Anticonvulsant therapy for status epilepticus. Cochrane Database Syst Rev 2014;
CD003723.
19) Atmaca MM, et al. Intravenous levetiracetam treatment in status epilepticus: a prospective study.
Epilepsy Res 2015; 114: 13-22.
20) Mundlamuri RC, et al. Management of generalised convulsive status epilepticus (SE): A
prospective randomised controlled study of combined treatment with intravenous lorazepam
with either phenytoin, sodium valproate or levetiracetam – Pilot study. Epilepsy Research 2015;
114: 52-8.
21) Gujjar AR, et al. Intravenous levetiracetam vs phenytoin for status epilepticus and cluster
seizures: A prospective, randomized study. Seizure 2017; 49: 8-12.
22) Chakravarthi S, et al. Levetiracetam versus phenytoin in management of status epilepticus. J Clin
Neurosci 2015; 22: 959-63.
23) Lyttle MD, et al. Levetiracetam versus phenytoin for second-line treatment of paediatric
convulsive status epilepticus (EcLiPSE): a multicentre, open-label, randomised trial. Lancet
2019; 393: 2125-34.
24) Nalisetty S, et al. Clinical Effectiveness of Levetiracetam Compared to Fosphenytoin in the
Treatment of Benzodiazepine Refractory Convulsive Status Epilepticus. Indian J Pediatr 2020;
87: 512-9.
25) Cock HR. Established Status Epilepticus Treatment Trial (ESETT). Epilepsia 2011; 52: 50-2.
26) Shih JJ, et al. Epilepsy treatment in adults and adolescents: Expert opinion, 2016. Epilepsy Behav
2017; 69: 186-222.
27) 久保田有一 他.【てんかん診療-すべての医師のための診断・治療のコツ-】てんかんの
最新治療 レベチラセタム（解説/特集）. 日本臨床 2018; 76: 952-8.
28) UPTODATE (This topic last updated: Jan 10, 2022)
29) Nakamura K, et al. Efficacy of levetiracetam versus fosphenytoin for the recurrence of seizures
after status epilepticus. Medicine 2017; 96: 25(e7206).
30) Nakamura K, et al. Changes in Real-world Practice Patterns of Antiepileptic Drugs for Status
Epilepticus: A Nationwide Observational Study in Japan. Neurol Med Chir 2020; 60: 156-63.
31) Nakamura K, et al. Levetiracetam vs. Fosphenytoin for Second-Line Treatment of Status
17